We examined the analytical performance of eight compact systems for measuring total cholesterol: AccuMeter, Cobas Ready, Discovery f2, DT6O, L-D-X, Refiotron, QCA, and Vision. We determined average bias at two decision levels, the mean absolute bias, and the percentage of results differing from the comparison method results by >8.9% allowable total error limit for multiple reagent lots. Average bias was <3% for all lots tested for AccuMeter, Discovery t2, and DT6O, but >3% for one or more lots or sample types tested with the other systems. Of results from each reagent lot, >95% were within the 8.9% total error specifications with Discovery f2, DT6O, and QCA, whereas the performance of L-D-X, Vision, and Reflotron depended on reagent lot and (or) sample type. Of all results from each lot tested with AccuMeter and Cobas Ready, >5% exceeded the total allowable error limit. We determined imprecision for five systems: Cobas Ready, Discovery f2, and QCA had CVs <3%, whereas CVs for AccuMeter and L-D-X were >3% but <5%. Ready, Discovery f2, L-D-X, and QCA., as well as the DT6O, Reflotron, and Vision, which have been widely used and evaluated previously. To determine how well these compact systems perform, in view of current analytical goals for cholesterol, we assessed precision and bias according to the LSP recommendations.
Ready, Discovery f2, L-D-X, and QCA., as well as the DT6O, Reflotron, and Vision, which have been widely used and evaluated previously. To determine how well these compact systems perform, in view of current analytical goals for cholesterol, we assessed precision and bias according to the LSP recommendations.
In addition, we determined the percentage of results differing from the comparison method value by more than the allowable total error. Accuracy studies included evaluation of two to four reagent and (or) calibrator lot combinations to assess consistency in performance. All manufacturers provided appropriate information or training for sample analysis, calibration, quality control, and maintenance.
Materials and Methods

Analysis Systems
The manufacturers' recommended procedures were followed throughout the evaluation by experienced laboratory personnel.
Method Evaluation
Precision. We evaluated precision of the AccuMeter, Cobas Ready, Discovery [2, L-D-X, and QCA by analyzing Boehringer Mannheim Cholesterol Controls Levels I and II in duplicate for 20 days (n = 40). These controls had been previously pooled, aliquoted, and frozen, and freshly thawed samples were used each day. We used only one reagent lot or one reagent/calibrator lot combination for the precision study. We calculated CVs for total, within-run, and between-day imprecision by using analysis of variance of one-stage, nested design (11).
Accuracy.
We We performed regression analysis of the evaluated analyzers vs the comparison method for each data set.3 We calculated percent average bias (and the 95% confidence limits) (13) at the 2.00 and 2.40 gIL medical decision levels. We also calculated the mean absolute percent bias for each reagent/calibrator lot combination tested, and determined the number and percentage of patients' samples exceeding the recommended 8.9% allowable total error limit for each lot, as well as for the total performance of the analyzers during the evaluation.
Comparison criteria.
For acceptable performance based on NCEP guidelines for measurement of total cholesterol (8), total CV must be <3%, bias must be <3%, and 95% of patients' results must be within 8.9% (allowable total error limit) of the comparison method value. We derived the allowable total error limit from the NCEP guidelines as follows: allowable total error = 1.96(CV) + bias!.
Hemolysis interference.
We added hemolysate to allquots of serum to prepare samples containing hemoglobin at 0, 0.50, 2.10, and 5.00 gIL. We added 50 g/L human albumin in saline for volume correction. We averaged results from duplicate analyses and calculated the percent change from the control (0 g/L hemoglobin). Table 1 summarizes our evaluation of precision for five compact analysis systems for measuring total cholesterol. The Cobas Ready, Discovery [2, and QCA demonstrated CVs for total imprecision of <3% for both levels of controls tested, thereby performing within LSP recommendations.
Results
The CVs for the AccuMeter and L-D-X were >3% but <5%.
As presented in Table 2 , the percent average bias at both the 2.00 and 2.40 g/L medical decision levels was within the <3% LSP recommendation for all reagent! calibrator lots and sample types tested for the AccuMeter, Discovery 12, and DT6O. Average bias was slightly >3% at one decision level for one reagent/calibrator lot combination when using the QCA and Vision. The average bias for the L-D-X was <3% for serum; however, the bias was slightly >3% in a trial with whole blood, ...#{149}... The AccuMeter is a hand-held, single-use, noninstrumented cartridge unit (10) that has been approved and will be marketed for home testing. When evaluated with NCEP performance criteria, the AccuMeter demonstrated imprecision of 4.7% and 3.5%, exceeding the 1992 LSP recommendations but meeting the pre-1992 guidelines of 5%. Most of the imprecision in the AccuMeter method is contributed by the within-run component (Table 1) , indicating variability in analysis between the individual test cartridges. Average bias was <1% for both lots tested at both medical decision levels, implying acceptable accuracy. However, 9.5% and 14.3% of results exceeded the 8.9% allowable total error limit for the two reagent lots tested (11.9% of all results).
3A
Thus, in this case, the use of average bias as a statistical tool is misleading, and the system does not appear to have sufficient accuracy when assessed with the mean absolute percent bias (4.9% and 5.5% for the two lots tested) or the allowable total error criterion with individual patients' samples. Improvements in precision would be expected to improve accuracy with re-4.0 spect to individual results.
The DT6O, Reflotron, and Vision were not included in the precision studies in this evaluation because they have been thoroughly evaluated previously.
Published precision results for these three systems are listed in Table 4 . The CVs reported for the DT6O, Reflotron, and Vision were <3% in 8 of 11, 3 of 17, and 5 of 7 reports, respectively.
As determined in this study, average bias was acceptable for all four reagent lots tested on the DT6O, whereas one of three Reflotron reagent lots and one of four Vision reagent lots displayed average bias >3% at one or both medical decision levels. When the number of results exceeding 8.9% total error was determined, the DT6O was found to be acceptable, with only 1 of 143 results exceeding the error limit. The performance of the Vision demonstrated a dependence on the reagent lot in this study; two of four reagent lots tested had no results outside the specified limits, whereas 8.3% and 5.9% of results from the other two lots had large errors. The accuracy of the Reflotron was better for serum than for whole blood; 5.6% of results for serum and 25.0% of results for whole blood differed from the comparison method values by >8.9%. When testing serum samples, one Reflotron lot was acceptable, one was borderline, and one was unacceptable.
Thus, of these three analyzers that have been extensively used and evaluated, only the DT6O produced reliable results consistently in this study. The Reflotron, however, performed within NCEP guidelines with one lot number in February 1992 for certification by the National Cholesterol Reference Method Laboratory Network (37).
The L-D-X, a small analyzer designed specifically for lipid testing, demonstrated imprecision in slight excess of the recommended 3% and, although average bias was acceptable for serum samples (0.1-1.9%), it was borderline (3.2%) with whole blood. Mean absolute bias was 2.9%-3.8%
for serum and 4.2% for whole blood. We found that 5.4% of L-D-X results for all serum samples exceeded the allowable total error limit, slightly above the recommended number. All of the 21 whole-blood samples tested were within 8.9% of the comparison method value. As with the AccuMeter, improvements in precision may decrease the number of samples exceeding the total error limit.
The Cobas Ready demonstrated acceptable precision but had excessive average and mean absolute bias. The magnitude and direction of the bias was found to be reagent lot-dependent. In conclusion, the DT6O and the Discovery [2 with the Total Cholesterol Test Kit measured total cholesterol precisely and accurately within all current LSP guidelines. The Vision and QCA demonstrated slight lotdependent bias, but whereas overall performance of the QCA was acceptable, the performance of the Vision was lot-dependent when total error of patients' samples was assessed.
The AccuMeter and L-D-X are imprecise as judged by current guidelines, probably contributing to the >5% of results exceeding the allowable total error limits. The Refiotron and the Cobas Ready also demonstrate lot-dependent bias and, according to published reports (see Table 4 ), the Refiotron may also be imprecise. The Refiotron was more accurate in measuring serum samples than whole blood, although acceptability of performance varied with reagent lot. The Cobas Ready must be considered unreliable because of the large number of results (32.9% overall and 6-78% depending on reagent lot) having total errors >8.9%.
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